One week ago, Matthew Perry’s autopsy report came back, finding that the ‘Friends’ actor died from the acute effects of ketamine overdose. His death has sharpened focus on the popular and controversial drug. Ketamine has been hailed as a miracle cure for depression and anxiety, criticized as a VC-fueled fad, and investigated as a placebo. But what is ketamine, what is its history, what do we know about how and why it works, and how could it help hundreds of millions of people with depression and anxiety? Today’s guest is Boris Heifets. He is an assistant professor of anesthesiology at Stanford University and the author of a much talked about and utterly fascinating study on ketamine that came up with a brilliant way to test the effects of ketamine. The study's surprising results raise big questions about not only ketamine, but the curative power of belief.

If you have questions, observations, or ideas for future episodes, email us at [email protected].

Host: Derek Thompson

Guest: Boris Heifets

Producer: Devon Baroldi

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s episode is about 2023 in media—from TV to film, from the miracle of Barbenheimer’s to the superhero drought, from Netflix’s show of strength to Taylor Swift’s invincibility, from the podcast purge to so much more. Our guest is Matt Belloni, the host of Ringer podcast ‘The Town’ and a writer with Puck.

If you have questions, observations, or ideas for future episodes, email us at [email protected].

Host: Derek Thompson

Guest: Matthew Belloni

Producer: Devon Baroldi

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s episode is our second in a series on the weight-loss drug revolution of the last two years.

On Tuesday, we talked to endocrinologist Beverly Tchang about the science of glucagon like peptide 1 receptor agonists—also known as GLP1s, also known as Ozempic, Wegovy, Moujargo, and Zepbound. If you haven’t listened to that show, I think you’ll feel safe and entertained within the bounds of this episode. But if you want to know more about how these drugs work, their effect on insulin and glucose and the brain’s reward center, or the questions they raise about obesity and the nature of willpower and free will, I’d encourage you to queue up that show.  Today, in Part 2, we have two guests: Zach Reitano is the CEO and cofounder of the telehealth platform Ro. He is here for a couple reasons. He has a bird’s-eye view of the GLP1 marketplace, the rise in demand, the supply chain, the economics of pricing and insurance. He’s also written several revelatory essays, pulling in research from think tanks, medical experts, and investment banks, that have helped shape my understanding of these drugs and the effect they could have on the population and the economy. Our second guest is Dr. Robert Lustig, an endocrinologist who spent years as a pediatrician and researcher at the University of California-San Francisco. As you’ll hear, he is much less optimistic about the ability of these drugs to revolutionize obesity medication in America.

If you have questions, observations, or ideas for future episodes, email us at [email protected].

Host: Derek Thompson

Guests: Zach Reitano & Robert Lustig

Producer: Devon Baroldi

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s podcast is about the weight-loss drug revolution—which I believe might be one of the most important stories in the world right now. Despite all the attention weight-loss drugs are receiving, it’s possible that they might soon affect the world even more than we realize as they teach us about the science of human metabolism, decision-making, and even free will. Beverly Tchang, an endocrinologist at Weill Cornell, explains how these drugs work, what they mean for people with diabetes and obesity, and how to wrap our minds around their stranger and spookier side effects.

If you have questions, observations, or ideas for future episodes, email us at [email protected].

Host: Derek Thompson

Guest: Beverly Tchang

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today, we’re examining the U.S. housing market, starting with a specific question: Should you look to rent or buy your next home? By some metrics, this is the worst time to buy a house in 40 years. Housing prices are near record highs, especially compared to local rents. For many young people, the dream of homeownership might seem completely impossible right now, thanks to huge national demand colliding with short supply, especially in high-income areas. Meanwhile, high mortgage interest rates have failed to reduce home prices, as owners are rate locked into their old mortgages. When will this sorry state of affairs turn around? Mark Zandi, the chief economist of Moody’s Analytics and host of the Inside Economics podcast, joins the show to answer our questions.

If you have questions, observations, or ideas for future episodes, email us at [email protected].

Host: Derek Thompson

Guest: Mark Zandi

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s episode is about the controversial life and legacy of Henry Kissinger, who died last week at the age of 100. First as Nixon’s National Security Advisor and Secretary of State, and then as an author and diplomacy whisperer in almost every subsequent administration, Kissinger's life is overstuffed with achievements and disasters and breakthroughs and catastrophes—many of which continue to shape the world we live in. Today’s guest is George Packer, an Atlantic staff writer and the author of several books, including ‘Our Man,’ a biography of Richard Holbrooke: another towering American diplomat who was Kissinger’s rival and partner in diplomacy.

If you have questions, observations, or ideas for future episodes, email us at [email protected]. 

Host: Derek Thompson

Guest: George Packer

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s episode is a wide-ranging one, from breaking news in tech to the philosophy of social media. The Atlantic's Charlie Warzel joins to discuss Elon Musk's bizarre and crude comments at The New York Times DealBook Summit, the corporate meltdown of X, whether its demise would make the world better off, the fragmentation of the social media landscape, and its implications for audiences and news-makers everywhere.

If you have questions, observations, or ideas for future episodes, email us at [email protected]. 

Host: Derek Thompson

Guest: Charlie Warzel

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices

This month, President Joe Biden and President Xi Jinping of the People's Republic of China (PRC) met in San Francisco amid trade wars and even the prospect of a catastrophic hot war over Taiwan. Their meeting took place during a nervous period in the history of China. After decades of spectacular growth, the Chinese economic miracle has sputtered, with huge implications for its own population and the world. And yet, even as the most dire aspects of the Chinese economy make headlines, it remains the case that China is the foundry of the green energy revolution, making more solar panels and wind turbines and electric vehicles than any other country. To help us understand how China thinks about economics, technology, and America, we welcome back to the show writer Dan Wang.

If you have questions, observations, or ideas for future episodes, email us at [email protected]. 

Host: Derek Thompson

Guest: Dan Wang

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s episode is about whatever the hell just happened—is still happening—at OpenAI, where CEO Sam Altman has been fired, almost rehired, and then shipped off to Microsoft, while the most famous startup in artificial intelligence self-immolates for reasons that the company refuses to explain. Our panel has some theories. Charlie Warzel is a staff writer at The Atlantic who has been texting and talking with OpenAI employees for the last few days. Karen Hao is a contributing writer at The Atlantic who is writing a book about OpenAI and knows many of the main characters from this past weekend. Ross Andersen is a staff writer at The Atlantic who wrote a big magazine feature on Sam Altman, OpenAI, and the messy quest to build artificial general intelligence.

If you have questions, observations, or ideas for future episodes, email us at [email protected]. 

Host: Derek Thompson

Guests: Ross Andersen, Karen Hao & Charlie Warzel 

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today’s episode is about the question of the moment in politics: the meaning of Joe Biden’s terrible polling numbers. Today’s guest is Nate Cohn, chief political analyst at the New York Times, where he does public opinion, polling, demographics, and politics. We talk about the notorious New York Times poll that showed Donald Trump trouncing Biden in the swing states. We talk about why it’s not crazy to take presidential polls seriously right now—even though we're 300 days out from the election. We talk about the multi-layered problems of Biden’s age. And we talk about why the new "engagement gap" might be the most important, under-discussed phenomenon in American politics today.

If you have questions, observations, or ideas for future episodes, email us at [email protected]. 

Host: Derek Thompson

Guest: Nate Cohn

Producer: Devon Manze

Learn more about your ad choices. Visit podcastchoices.com/adchoices